gdc
Ovarian Cancer

Zejula Approved for HRD-Positive Advanced Ovarian Cancer

Late last year, the PARP inhibitor Zejula was approved by the FDA for patients with HRD mutation associated with advanced ovarian, fallopian tube, or primary peritoneal cancer, offering a new treatment option for women with these types of cancer.
December 2019 Vol 5 No 6

In October 2019, the FDA approved a new indication for the PARP inhibitor Zejula (niraparib; from Tesaro) for the treatment of patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer, after receiving at least 3 chemotherapy regimens.

HRD is a type of genetic mutation defined by a deleterious or suspected deleterious BRCA mutation, or a genomic instability associated with disease progression more than 6 months after the tumor’s response to the last platinum-based chemotherapy.

Zejula has been previously approved by the FDA as maintenance treatment for patients these types of ovarian cancer but without HRD mutation.

Together with this new approval, the FDA also approved a new genetic test called Myriad myChoice CDx test, to identify patients with HRD mutation for Zejula therapy.

This new approval of Zejula was based on results of a clinical trial of patients with HRD-positive advanced ovarian cancer. Among the patients with HRD-positive status, 24% responded to treatment with Zejula, and the average duration of response was 8.3 months. Among patients with ovarian cancer and BRCA mutations, between 39% and 19% of patients responded to therapy with Zejula, depending on their response to platinum-based therapy.

Overall, 7% of patients had side effects with Zejula that required dose reduction or dose interruption, mostly because of infection, anemia, neutropenia, nausea, vomiting, fatigue, and abdominal pain.

Share this:

Recommended For You
FDA Approvals, News & UpdatesOvarian Cancer
Zejula Approved as Once-Daily Treatment Option in Women with Advanced Ovarian Cancer
Women with advanced ovarian cancer now have a new once-daily treatment option. In April 2020, the Food and Drug Administration (FDA) approved Zejula (niraparib) for the maintenance treatment of all women with advanced ovarian cancer (including epithelial cancer, fallopian tube cancer, and primary peritoneal cancer) who have responded well to first-line chemotherapy. Maintenance therapy is the treatment of cancer with medication, typically following a first round of treatment (in this case, platinum-based chemotherapy).
Ovarian Cancer
Drugs for Ovarian Cancer
Here are the drugs and financial support services available to patients receiving treatment for Ovarian Cancer.
Ovarian CancerSurvivorship
SOAR Beyond the Trauma of a Cancer Diagnosis
By Tiffany R. Easley
Diagnosed with ovarian cancer at age 3, Tiffany R. Easley learned the power of owning one’s story, detailing her powerful “SOAR” survivor mindset.
Ovarian CancerSurvivorship
Listen to the Voices of Cancer Survivors
By Annette Bennington McElhiney, PhD
Annette McElhiney, PhD, notes the psychosocial needs of patients with cancer, survivors, and caregivers. As an ovarian cancer survivor, she describes the help provided by the recently launched “Steps Through Ovarian Cancer” program.
Last modified: May 4, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country